The CEO of Google Mind has suggested clinical trials of the first drugs designed with the help of AI could begin this year.
Google's DeepMind spinoff Isomorphic Labs expects clinical trials of drugs designed using AI to start late this year.
Drugs developed by Alphabet’s drug discovery subsidiary and designed by artificial intelligence are expected to head to trial by the end of the year, according to a Google (GOOGL) executive.
An Alphabet-backed startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end.
Alphabet’s artificial intelligence start-up Isomorphic Labs has made a splash at the start of the JP Morgan Healthcare conference this week, announcing its first pharma partnerships with Eli ...
DeepMind’s new AlphaFold 3 expands to DNA, RNA modeling Google DeepMind expands its AlphaFold AI system to model how proteins interact with other cell structures including DNA and RNA.
The pharma giant is partnering with software firms to imagine new drugs, find targets, and design clinical trials ...
Pharmaceutical firms that specialize in utilizing AI to speed up the drug discovery process are soaring today.